ClinicalTrials.gov - PCO-02 - Safety and Pharmacokinetics Trial (NCT02637284): Specific details of the Phase 1 trial
Desrochers T, Suter-Dick L, Roth A, Kaplan D (2013) Bioengineered 3D human kidney tissue, a platform for the determination of nephrotoxicity
For every day liver support, take 2 capsules daily (with food)
You may need a course of injections, but once completed, you should see some shapely results in the following weeks
The human glutathione transferase P1-1 specific inhibitor TER 117 designed for overcoming cytostatic-drug resistance is also a strong inhibitor of glyoxalase I
These tips come from clinical guidance, nursing best practices, and the collective experience of thousands of self-injectors